Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP ; volume:18 ; number:1 ; day:12 ; month:9 ; year:2023 ; pages:1-14 ; date:12.2023
Molecular neurodegeneration ; 18, Heft 1 (12.9.2023), 1-14, 12.2023
- Creator
-
Chiotis, Konstantinos
Johansson, Charlotte
Rodriguez-Vieitez, Elena
Ashton, Nicholas J.
Blennow, Kaj
Zetterberg, Henrik
Graff, Caroline
Nordberg, Agneta
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13024-023-00647-y
- URN
-
urn:nbn:de:101:1-2024020112465589151547
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chiotis, Konstantinos
- Johansson, Charlotte
- Rodriguez-Vieitez, Elena
- Ashton, Nicholas J.
- Blennow, Kaj
- Zetterberg, Henrik
- Graff, Caroline
- Nordberg, Agneta
- SpringerLink (Online service)
Other Objects (12)
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s disease
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias